

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended). A method for measuring cyclin-dependent kinase (CDK) activity in a sample, said method comprising:

- i) contacting said sample with an anti-retinoblastoma protein (Rb) capture antibody, that specifically recognizes Rb protein phosphorylated at Ser249, Thr252, Thr356, Ser612, Ser780, Ser807, Ser811, or Thr821, and isolating the capture antibody-Rb complex;
- ii) contacting said capture antibody-Rb complex with an anti-Rb primary antibody and isolating the capture antibody-Rb-primary antibody complex; and
- iii) measuring the amount of CDK-phosphorylated Rb in said sample by quantitating the primary antibody present in said capture antibody-Rb-primary antibody complex.

Claim 2 (original). The method of claim 1, wherein said CDK is CDK2.

Claim 3 (original). The method of claim 1, wherein said CDK is CDK4.

Claim 4 (original). The method of claim 1, wherein said method measures intracellular CDK activity.

Claim 5 (original). The method of claim 4, wherein said method measures CDK activity in a cultured cell.

Claim 6 (original). The method of claim 4, wherein said method measures *ex vivo* CDK activity in a cell taken from an animal.

Claim 7 (original). The method of claim 1, wherein said CDK activity is human CDK activity.

Claim 8 (original). The method of claim 1, wherein said capture antibody is bound to a test plate.

Claims 9-19 (canceled).

Claim 20 (original). The method of claim 4, wherein said method measures *ex vivo* CDK activity in a cell taken from an animal.

Claims 21-23 (canceled).